Table 1 Baseline characteristic of studies included in the systematic review and meta-analysis
Author | Publication year | Country | Study design | Disease stage | Percentage of adenocarcinoma (%) | Sample size | Mean age (years) | Percentage male (%) | Percentage of smoker (%) | Percentage of TKI (%) | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|
Hsiao [14] | 2013 | China | Retrospective | I–IV | 100.0 | 139 | NA | 41.0 | 30.0 | 32.0 | 7 |
Han [20] | 2016 | China | Retrospective | I–IV | 100.0 | 234 | NA | 53.4 | 44.0 | 30.3 | 8 |
Russo [21] | 2017 | Italy | Retrospective | IIIb-IV | 73.0 | 137 | 66.2 | 59.1 | 77.4 | NA | 6 |
Baek [15] | 2016 | Korea | Retrospective | IV | 70.0 | 259 | 68.0 | 64.5 | 59.1 | NA | 7 |
Stanic [22] | 2014 | Slovenia | Retrospective | I–IV | 100.0 | 629 | 64.0 | 51.8 | 72.0 | NA | 8 |
Hsu [16] | 2016 | Canada | Retrospective | IV | NA | 543 | 66.0 | 40.0 | NA | 41.0 | 7 |
Hendriks [23] | 2014 | The Netherlands | Retrospective | NA | 91.9 | 124 | 61.9 | 41.9 | 72.6 | 37.1 | 8 |
Iuchi [17] | 2014 | Japan | Retrospective | Ia-IV | 79.4 | 1127 | 67.0 | 65.2 | 64.2 | 42.3 | 5 |
Arrieta [30] | 2009 | Mexico | Prospective | IIIb-IV | 64.8 | 293 | 60.7 | 56.0 | 53.9 | 12.6 | 6 |
Lee [24] | 2012 | China | Retrospective | I-III | 93.0 | 43 | 59.0 | 53.0 | 37.0 | 44.0 | 5 |
Iuchi [18] | 2013 | Japan | Prospective | NA | 100.0 | 41 | NA | 29.3 | 21.9 | NA | 5 |
Li [25] | 2015 | China | Retrospective | NA | 83.8 | 136 | NA | 52.9 | 58.8 | 30.9 | 7 |
Luo [31] | 2013 | China | Retrospective | I-IV | 82.4 | 136 | 55.0 | 61.0 | 37.5 | 5.1 | 6 |
Zhuang [26] | 2013 | China | Prospective | I-IV | 100.0 | 54 | 61.7 | 42.6 | NA | 42.6 | 7 |
Tomasini [27] | 2016 | France | Retrospective | IV | 89.4 | 142 | 62.0 | 66.2 | 76.1 | NA | 6 |
Eichler [19] | 2010 | US | Retrospective | I-IV | 94.0 | 93 | 60.9 | 33.0 | 57.0 | 19.0 | 8 |
Mak [28] | 2015 | US | Retrospective | NA | NA | 172 | 60.0 | 45.0 | 70.0 | 42.0 | 6 |
Wang [29] | 2015 | US | Retrospective | I-III | 85.9 | 71 | 61.9 | 50.7 | NA | 21.1 | 5 |